CTLA4 and neoplasm: In addition, some patients receiving anti-CTLA-4 monoclonal Ab (mAb) and anti-PD-1 mAb have shown resistance to ICIs to varying degrees due to tumor-extrinsic and/or -intrinsic factors (8–10).